TAK 003

Drug Profile

TAK 003

Alternative Names: Dengue vaccine tetravalent - Takeda Pharmaceuticals; DENVax™ - Takeda Pharmaceuticals; Needle-free dengue vaccine; TAK 003; Tetravalent dengue vaccine - Takeda Pharmaceuticals

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda Pharmaceuticals USA
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dengue

Most Recent Events

  • 05 Apr 2017 Takeda completes enrolment in the TIDES trial for Dengue (In adolescents, In children, Prevention) in Panama, Brazil, Colombia, Nicaragua, Thailand, Philippines, Sri Lanka and the Dominican Republic (SC)
  • 03 Apr 2017 Takeda initiates enrolment in a phase II trial for Dengue (In adolescents, In children, Prevention) in Philippines and Panama (NCT02948829)
  • 29 Mar 2017 Interim efficacy and adverse event data from a phase II DEN-204 trial in Dengue released by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top